)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Oric Pharmaceuticals
Oric Pharmaceuticals (ORIC) investor relations material
Oric Pharmaceuticals 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Pipeline overview and strategic focus
Two late-stage assets: rinzimetostat for prostate cancer and enozertinib for lung cancer, both advancing toward phase III trials in 2025-2026.
Cash runway extends into the second half of 2028, supporting key data readouts and trial initiations.
Management team has extensive experience in oncology drug development, contributing to operational resilience.
Both drugs target high unmet need populations with significant commercial potential.
Multiple clinical collaborations with major pharma partners for combination studies.
Rinzimetostat (prostate cancer) program
PRC2 inhibitor developed in combination with leading AR inhibitors (apalutamide, darolutamide).
Demonstrated higher PSA response rates and ctDNA clearance compared to standard AR inhibitors and competitor data.
Safety profile appears more favorable than competitor (Pfizer's mevrometostat), with less frequent and less intense toxicity.
Phase III study initiation expected in the first half of 2025, with primary data readout anticipated in the second half of 2027.
Dose optimization data for key patient populations to be disclosed in Q1 2025, focusing on efficacy and safety.
Enozertinib (lung cancer) program
Selective, brain-penetrant TKI targeting EGFR exon 20 and PACC mutations in non-small cell lung cancer.
Achieved 100% intracranial response rate in patients with measurable CNS disease, a key differentiator.
Systemic response rates match or exceed competitors, with strong activity in both frontline and pretreated settings.
Well-tolerated safety profile and phase III dose selected; new data expected in the second half of 2026.
Substantial commercial opportunity due to the size and unmet need of target populations.
How will rinzimetostat's safety profile drive adoption?
Enozertinib's 100% intracranial ORR: next steps?
Rinzimetostat Q1 data: key for Phase III success?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Oric Pharmaceuticals earnings date
Q4 202517 Feb, 2026
Oric Pharmaceuticals
Next Oric Pharmaceuticals earnings date
Q4 202517 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Oric Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies aimed at overcoming resistance in cancer. The company is dedicated to addressing one of the most significant challenges in oncology by targeting resistance mechanisms to improve the efficacy and durability of cancer treatments. Oric's research is concentrated on three primary resistance pathways: innate resistance, acquired resistance, and bypass resistance. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage